Patents Assigned to Glycart Biotechnology AG
-
Patent number: 7906329Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.Type: GrantFiled: May 14, 2003Date of Patent: March 15, 2011Assignee: Glycart Biotechnology AGInventors: Pablo Umana, Joel Jean-Mairet, James E Bailey
-
Patent number: 7846432Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: August 17, 2007Date of Patent: December 7, 2010Assignee: GlycArt Biotechnology AGInventors: Pablo Umaña, Ekkehard Mössner
-
Patent number: 7727741Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: August 17, 2007Date of Patent: June 1, 2010Assignee: GlycArt Biotechnology AGInventors: Pablo Umaña, Ekkehard Mössner
-
Patent number: 7722867Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: February 7, 2006Date of Patent: May 25, 2010Assignee: Glycart Biotechnology AGInventors: Pablo Umaña, Ekkehard Mössner
-
Patent number: 7662377Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: August 9, 2007Date of Patent: February 16, 2010Assignee: Glycart Biotechnology AGInventors: Pablo Umaña, Ekkehard Mössner
-
Publication number: 20090304690Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.Type: ApplicationFiled: March 23, 2009Publication date: December 10, 2009Applicant: GLYCART BIOTECHNOLOGY AGInventors: PABLO UMANA, JOEL JEAN-MAIRET, JAMES E. BAILEY, Sean Bailey
-
Publication number: 20090232817Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 17, 2007Publication date: September 17, 2009Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Ekkehard Mossner
-
Publication number: 20090186019Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 17, 2007Publication date: July 23, 2009Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Ekkehard Mossner
-
Patent number: 7517670Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.Type: GrantFiled: August 5, 2003Date of Patent: April 14, 2009Assignee: GlycArt Biotechnology AGInventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey, legal representative, James E Bailey
-
Publication number: 20090010921Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 17, 2007Publication date: January 8, 2009Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Peter Brunker, Claudia Ferrara, Tobias Suter, Ursula Puntener, Ekkehard Mossner
-
Publication number: 20080286277Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 17, 2007Publication date: November 20, 2008Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Ekkehard Mossner
-
Publication number: 20080280322Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.Type: ApplicationFiled: August 9, 2005Publication date: November 13, 2008Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Joel Jean-Mairet, James Bailey
-
Publication number: 20080279858Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: February 7, 2006Publication date: November 13, 2008Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Ekkehard Mossner
-
Publication number: 20080095770Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 9, 2007Publication date: April 24, 2008Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Ekkehard Mossner
-
Publication number: 20070111281Abstract: The present invention is directed to antigen binding molecules, including antibodies, comprising a Fc region having one or more amino acid modifications, wherein the antigen binding molecule exhibits altered binding to one or more Fc receptors as a result of the modification(s). The invention is further directed to polynucleotides and vectors encoding such antigen binding molecules, to host cells comprising the same, to methods for making the antigen binding molecules of the invention, and to their use in the treatment of various diseases and disorders, e.g., cancers.Type: ApplicationFiled: May 9, 2006Publication date: May 17, 2007Applicant: GLYCART BIOTECHNOLOGY AGInventors: Peter Sondermann, Claudia Ferrara Koller, Peter Brunker, Fiona Stuart, Pablo Umana
-
Publication number: 20060269545Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: February 7, 2006Publication date: November 30, 2006Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Ekkehard Mossner
-
Publication number: 20060223096Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human MCSP. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: March 24, 2006Publication date: October 5, 2006Applicant: GLYCART BIOTECHNOLOGY AGInventors: Pablo Umana, Ekkehard Mossner
-
Publication number: 20050272128Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.Type: ApplicationFiled: August 9, 2005Publication date: December 8, 2005Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Joel Jean-Mairet, James Bailey
-
Publication number: 20050123546Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: November 5, 2004Publication date: June 9, 2005Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Peter Brunker, Claudia Ferrara, Tobias Suter, Ursula Puntener, Ekkehard Mossner
-
Publication number: 20040241817Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: January 22, 2004Publication date: December 2, 2004Applicant: GlycArt Biotechnology AGInventors: Pablo Umana, Peter Bruenker, Claudia Ferrara, Tobias Suter